Xencor

Xencor, Inc. is a clinical-stage biopharmaceutical company headquartered in Monrovia, California, that specializes in the discovery and development of engineered monoclonal antibodies and protein therapeutics aimed at treating severe and life-threatening diseases. The company utilizes its proprietary XmAb technology platform to create a range of antibody product candidates targeting conditions such as cancer and autoimmune diseases. Notable candidates include XmAb5871 and XmAb7195, which have completed various phases of clinical trials, and XmAb14045, currently in Phase I for acute myeloid leukemia. Xencor also develops bispecific antibodies, such as AMG424 and AMG509, which are in different stages of clinical and preclinical development for various cancers. The company generates revenue through research and development collaborations and licensing agreements with several prominent pharmaceutical organizations. Founded in 1997, Xencor is focused on addressing unmet medical needs through innovative therapeutic solutions.